Quantification of bone flare on ¹⁸F-NaF PET/CT in metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

Bone flare has been observed on ^99mTc-MDP bone scans of patients with metastatic castration-resistant prostate cancer (mCRPC). This exploratory study investigates bone flare in mCRPC patients receiving androgen receptor (AR) inhibitors using ¹⁸F-NaF PET/CT.

Methods

Twenty-nine mCRPC patients undergoing AR-inhibiting therapy (abiraterone, orteronel, enzalutamide) received NaF PET/CT scans at baseline, week 6, and week 12 of treatment. SUV metrics were extracted globally for each patient (SUV) and for each individual lesion (iSUV). Bone flare was defined as increasing SUV metrics or lesion number at week 6 followed by subsequent week 12 decrease. Differences in metrics across timepoints were compared using Wilcoxon tests. Cox proportional hazar

SUBMITTER: Weisman AJ 

PROVIDER: S-EPMC7490782 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature